BIODESIX INC

Biodesix’s cutting‑edge blood tests for non‑small cell lung cancer are reshaping cancer diagnostics—discover how the Boulder‑based biotech is driving better patient outcomes.

Biodesix’s Q2 2026 earnings reveal a high‑risk, high‑reward diagnostics firm poised to transform lung cancer care—investors see a 6% upside amid cautious optimism.

Biodesix unveils its 2025 R&D roadmap, celebrates IPO anniversary and Nasdaq compliance, spotlighting new lung‑cancer serum tests and strategic partnerships.

Biodesix Inc. is navigating market volatility through proactive investor engagement and a focus on healthcare innovation, despite experiencing significant stock price fluctuations.

Biodesix Inc. has announced its first-quarter 2025 results, with its stock price experiencing a significant drop from its 52-week high, but the company remains committed to advancing its mission in diagnostic capabilities in oncology.